Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00733304 |
This is a two month study to allow continued treatment with pazopanib eye drops. Study may be extended to 5 months.
Condition | Intervention | Phase |
---|---|---|
Macular Degeneration |
Drug: Pazopanib (5 mg/mL, TID) for 28 days,Pazopanib (2 mg/mL, TID) for 28 days,Pazopanib (5 mg/mL, QD) for 28 days |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Parallel Assignment, Pharmacodynamics Study |
Official Title: | An Extension Study to Protocol MD7108240: Pazopanib Eye Drops in Subjects With Neovascular Age-related Macular Degeneration |
Estimated Enrollment: | 99 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | May 2009 |
Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: US GSK Clinical Trials Call Center | 877-379-3718 |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | MD7111396 |
Study First Received: | August 12, 2008 |
Last Updated: | August 13, 2009 |
ClinicalTrials.gov Identifier: | NCT00733304 History of Changes |
Health Authority: | United States: Food and Drug Administration; Australia: Department of Health and Ageing Therapeutic Goods Administration; Italy: Ministry of Health |
pazopanib age-related macular degeneration (AMD) choroidal neovascularization (CNV) vascular endothelial growth factor (VEGF) angiogenesis |
Eye Diseases Mitogens Retinal Degeneration Macular Degeneration Tetrahydrozoline |
Neovascularization, Pathologic Endothelial Growth Factors Retinal Diseases Choroidal Neovascularization |
Eye Diseases Retinal Degeneration Macular Degeneration Retinal Diseases |